Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
Latest entries
- Trial result
Brain and CNS tumors
IDH1-vac (IDH1R132H peptide vaccine) links immune response to long OS in IDH1-mutant astrocytoma
IDH1-vac is a mutation-specific long-peptide vaccine targeting the shared clonal driver neoepitope IDH1R132H (MHC class II–restricted) and was integrated with standard-of-care chemoradiation in the multicenter,…
NCT02454634 - Trial result
Prostate cancer
pTVG-HP (PAP DNA vaccine) signals OS benefit in PSA-recurrent nonmetastatic prostate cancer vs placebo
pTVG-HP is a plasmid DNA vaccine encoding prostatic acid phosphatase (PAP), administered with GM-CSF, evaluated in a randomized Phase 2 trial in PSA-recurrent, nonmetastatic, noncastrate prostate cancer…
NCT01341652 - Trial result
Prostate cancer
Enzalutamide (AR inhibitor) benefit in mHSPC concentrates in APIC-negative tumors (OS HR 0.50), not APIC-positive (HR 1.04)
APIC is a locked AI histopathology classifier applied to baseline H&E prostate cancer specimens to predict differential benefit from enzalutamide (androgen receptor inhibitor) added to ADT in mHSPC. In this…
NCT02446405 - Trial result
Prostate cancer
Darolutamide (AR antagonist) triplet delays mCRPC (HR 0.36) without worsening pain/QoL in mHSPC
Darolutamide is an oral androgen receptor (AR) antagonist evaluated as “triplet therapy” with androgen deprivation therapy (ADT) plus docetaxel in the Phase III ARASENS trial (NCT02799602) in metastatic…
NCT02799602 - Trial result
Prostate cancer
Ablative MDT (PSMA-PET–guided SBRT) prolongs time to PSA progression in oligometastatic CRPC (interim Phase II)
In a single-centre randomized Phase II trial, PSMA-PET–guided metastasis-directed therapy (MDT; ablative radiotherapy to ≤5 PSMA-positive bone/lymph node metastases) was tested in castration-resistant prostate cancer…
NCT04141709 - Trial result
Multiple solid tumors
Pembrolizumab (PD-1 blockade) + AI-derived iTIL/“tumor content” dynamics predict survival in rare-tumor basket trial
Pembrolizumab is an anti–PD-1 immune checkpoint inhibitor evaluated in a Phase II, multi-cohort rare-tumor basket study (n=84) with paired baseline (256) and on-treatment (248) biopsies analyzed on H&E using a deep…
- Trial result
Uterine (endometrial) cancer
Cediranib (VEGFR TKI) + weekly paclitaxel lifts early disease control/ORR in platinum-pretreated endometrial cancer—but benefit washes out by 6 months
Cediranib is an oral VEGFR1-3–targeting anti-angiogenic TKI; in COPELIA (UK multicentre, open-label, randomized Phase 2; NCT03570437), patients with advanced/recurrent endometrial cancer after ≥1 prior platinum…
NCT03570437 - Trial result
Uterine (endometrial) cancer
Niraparib (PARP inhibitor) + dostarlimab (PD-1) maintenance cuts PFS risk ~40% in advanced/recurrent endometrial cancer—at major toxicity cost, no OS gain
Niraparib is an oral PARP inhibitor added to dostarlimab (anti–PD-1) maintenance after induction dostarlimab + carboplatin/paclitaxel in Part 2 of the Phase 3 ENGOT-EN6-NSGO/GOG-3031/RUBY trial (NCT03981796). In…
NCT03981796 - Trial result
Skin cancer (non-melanoma)
Neoadjuvant PD-1 checkpoint blockade is associated with longer EFS/OS in resectable periauricular cSCC vs upfront surgery
In a retrospective, age- and stage-matched tertiary-center series of periauricular cutaneous squamous cell carcinoma (pCSCC) treated 2005–2025, neoadjuvant immunotherapy (checkpoint blockade; drug(s) not specified in…
- Trial result
Head and neck cancer
Pembrolizumab (PD-1) + Quad‑Shot RT (14.8Gy/4fx) Delivers 47% ORR in Recurrent/Metastatic HNSCC
Pembrolizumab is an anti–PD‑1 immune checkpoint inhibitor; quad‑shot radiotherapy (QSRT) is a low-dose hypofractionated regimen (14.8Gy in four 3.7Gy fractions BID over 2 days) intended to improve local control and…
NCT04454489 - Trial result
Head and neck cancer
Metformin (AMPK modulation) + pembrolizumab (PD-1) posts 50% ORR in metastatic HNSCC feasibility Phase 2
Metformin ER (up-titrated to 2000mg daily) was combined with pembrolizumab 200mg q3w in a randomized Phase 2 feasibility study in recurrent/metastatic HNSCC (NCT04414540), with sequencing (metformin lead-in vs…
NCT04414540 - Trial result Spotlight
Ovarian cancer
Rezatapopt (p53 Y220C reactivator) drives 46% ORR in heavily pretreated TP53 Y220C ovarian cancer
Rezatapopt is an oral, first-in-class small-molecule “p53 reactivator” that selectively binds mutant TP53 Y220C, stabilizes p53 in a wild-type–like conformation, and aims to restore tumor-suppressor function. In the…
NCT04585750 - Trial result Spotlight
Ovarian cancer
Fulvestrant + abemaciclib enables cytoreduction in unresectable LGSOC
Fulvestrant is an intramuscular selective estrogen receptor degrader, and abemaciclib is an oral CDK4/6 inhibitor targeting ER-driven cell-cycle signaling. In a pilot Phase 2 neoadjuvant study in advanced, initially…
NCT03531645 - Trial result
Ovarian cancer
KRAS-mutant mesonephric-like ovarian adenocarcinoma shows 17.5-mo median PFS and “cotton candy” ultrasound signature
Mesonephric-like adenocarcinoma (MLA) is a rare ovarian carcinoma subtype (WHO 2020) that appears molecularly KRAS-driven; in this prospective, single-center observational series (Jan 2020–Dec 2023), 14/467 ovarian…
- Trial result
Liver and bile duct cancer
Atezolizumab (PD-L1) + bevacizumab (VEGF) in HCC: “on-target” TRAEs (renal/vascular/skin) track with longer OS
Atezolizumab is an anti–PD-L1 antibody and bevacizumab is an anti-VEGF antibody; this post hoc exploratory analysis pooled patients from IMbrave150 (NCT03434379) and GO30140 (NCT02715531) to test whether adverse…
NCT03434379 - Trial result Spotlight
Kidney cancer
Pembrolizumab + belzutifan (HIF-2α) improves adjuvant DFS in high-risk ccRCC—at a clear G3+ toxicity cost
Pembrolizumab is a PD-1 antibody and belzutifan is an oral hypoxia-inducible factor-2α (HIF-2α) inhibitor; in LITESPARK-022 (Phase 3, double-blind; NCT05239728), patients with resected clear-cell RCC at increased…
NCT05239728 - Trial result
Kidney cancer
OMNIVORE supports nivolumab stop-early responders, not salvage ipilimumab
Nivolumab is a PD-1 checkpoint inhibitor, and ipilimumab is a CTLA-4 checkpoint inhibitor; OMNIVORE tested response-adapted immunotherapy in advanced RCC (Phase 2; NCT03203473). Among 83 patients, early nivolumab…
NCT03203473 - Trial result
Kidney cancer
Casdatifan (HIF-2α inhibitor) drives 31–35% ORR with ~12.2-mo PFS in refractory metastatic ccRCC
Casdatifan is an orally bioavailable, potent and selective small-molecule HIF-2α inhibitor evaluated as monotherapy in the ARC-20 dose-expansion study (NCT05536141) in refractory metastatic clear cell renal cell…
NCT05536141 - Trial result
Stomach and esophageal cancer
Tislelizumab (PD-1) + CAPOX vs CAPOX/FOLFOX Chemo Backbone Shows No Clear PFS/ORR Win in 1L HER2− GC/GEJ (MAIC)
Tislelizumab is an anti–PD-1 monoclonal antibody combined here with fluoropyrimidine/platinum chemotherapy (CAPOX or FOLFOX) for first-line unresectable/metastatic HER2-negative gastric/gastroesophageal junction…
NCT03777657 - Trial result
Stomach and esophageal cancer
Zongertinib + T-DXd Shows Early Responses in Trastuzumab-Pretreated HER2+ mGEAC
Zongertinib is an oral, irreversible HER2-selective TKI designed to spare wild-type EGFR, here combined with trastuzumab deruxtecan (T-DXd), a HER2-directed topoisomerase I ADC, in Cohort C of the Phase Ib/II Beamion…
NCT06324357 - Trial result Spotlight
Non-small cell lung cancer
Ivonescimab (PD-1×VEGF bispecific) + pemetrexed/carboplatin extends OS after EGFR-TKI in NSCLC
Ivonescimab is a bispecific antibody that simultaneously targets PD-1 (checkpoint inhibition) and VEGF (anti-angiogenesis), aiming to pair immunotherapy with VEGF-pathway blockade in EGFR-variant nonsquamous NSCLC.…
NCT05184712 - Trial result
Non-small cell lung cancer
Alectinib (ALK TKI) shows bigger PFS edge in low tumor burden ALK+ NSCLC
A pooled individual patient-level analysis of the randomized Phase III ALEX (NCT02075840) and J-ALEX (JapicCTI-132316) trials compared first-line alectinib (a next-generation ALK tyrosine kinase inhibitor with CNS…
NCT02075840 - Trial result
Non-small cell lung cancer
Camrelizumab (PD-1) + chemo delivers 33% pCR in resectable stage III NSCLC, with ctDNA flagging relapse early
Camrelizumab is an anti–PD-1 monoclonal antibody given here with platinum-based chemotherapy as 3-cycle neoadjuvant chemoimmunotherapy in a single-arm Phase II study of resectable stage IIIA–IIIB NSCLC (n=30; 27…
NCT06241807 - Trial result
Non-small cell lung cancer
Encorafenib + binimetinib (BRAF/MEK inhibition) validates FoundationOne Liquid/Tissue CDx for BRAF V600E NSCLC selection
FoundationOne®Liquid CDx (F1LCDx; plasma ctDNA) and FoundationOne®CDx (F1CDx; tissue) are FDA-approved companion diagnostics for identifying BRAF V600E–mutant metastatic NSCLC patients eligible for encorafenib…
NCT03915951 - Trial result
Non-small cell lung cancer
Baseline PPIs correlate with sharply worse durvalumab outcomes in PACIFIC
Durvalumab is a PD-L1 antibody used as 12-month consolidation after concurrent chemoradiotherapy in unresectable stage III NSCLC. In a post-hoc analysis of PACIFIC treated patients consenting to exploratory analyses…
- Trial result Spotlight
Myeloproliferative neoplasms
Navitoclax (BCL-2/BCL-XL inhibitor) + ruxolitinib doubles Week-24 spleen responses in frontline myelofibrosis, with major cytopenias
Navitoclax (NAV), an oral BCL-2/BCL-XL inhibitor that can potentiate apoptosis but predictably worsens platelet counts via BCL-XL inhibition, was combined with the JAK1/2 inhibitor ruxolitinib (RUX) in the Phase 3…
NCT04472598 - Trial result
Other blood cancers and transplant
Tagraxofusp (CD123-directed cytotoxin) in BPDCN delivers 71%–90% ORR across trials—HSCT bridge drives survival
Tagraxofusp (tagraxofusp-erzs; ELZONRIS) is an IL-3Rα/CD123-targeted recombinant fusion “cytotoxin” (IL-3 linked to truncated diphtheria toxin) evaluated in a systematic review of adult BPDCN outcomes across…
NCT02113982 - Trial result
Sarcoma and GIST
Brigimadlin (MDM2–p53 antagonist) Misses PFS Endpoint vs Doxorubicin in 1L DDLPS, Despite Higher ORR
Brigimadlin (BI 907828) is an oral small-molecule MDM2 inhibitor that disrupts MDM2–p53 binding to reactivate TP53 signaling, and was tested against standard first-line doxorubicin in Brightline-1 (randomized Phase…
NCT05218499 - Trial result
Liver and bile duct cancer
Durvalumab (PD-L1) + GemCis Extends 4-Year Survival in 1L Advanced Biliary Tract Cancer
Durvalumab is an anti–PD-L1 monoclonal antibody added to gemcitabine/cisplatin (GemCis) in the global, double-blind Phase 3 TOPAZ-1 first-line aBTC trial (NCT03875235). In this 4-year post hoc update (data cutoff…
NCT03875235 - Trial result
Liver and bile duct cancer
KRAS-mutant biliary tract cancer predicts shorter PFS on durvalumab + Gem/Cis
Gemcitabine/cisplatin plus durvalumab (GCD; PD-L1 blockade) was evaluated retrospectively in advanced biliary tract cancer patients treated front line at MSK with pretreatment tumor sequencing (n=236; 56%…
NCT01775072
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.